Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

Copanlisib is a pan–class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of ta...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Blood Adv
Autori principali: Tarantelli, Chiara, Lange, Martin, Gaudio, Eugenio, Cascione, Luciano, Spriano, Filippo, Kwee, Ivo, Arribas, Alberto J., Rinaldi, Andrea, Jourdan, Thibaud, Berthold, Melanie, Sturz, Andrea, Sperl, Carolyn, Margheriti, Francesco, Scalise, Lorenzo, Gritti, Giuseppe, Rossi, Davide, Stathis, Anastasios, Liu, Ningshu, Zucca, Emanuele, Politz, Oliver, Bertoni, Francesco
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Hematology 2020
Soggetti:
Lymphoid Neoplasia
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065481/
https://ncbi.nlm.nih.gov/pubmed/32126142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000844
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi